The ratings of eight Biotechnology stocks are down this week, according to the database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
AMAG Pharmaceuticals (NASDAQ:) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, AMAG also gets F’s. The stock price has fallen 10% over the past month, worse than the 3% decrease the Nasdaq has seen over the same period of time. .
ArQule (NASDAQ:) ratings are on the decline this week as the company earns a F (“strong sell”). Last week, it received a D (“sell”). ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. The stock also rates an F in Sales Growth. .
This week, Momenta Pharmaceuticals (NASDAQ:) drops from a D to a F rating. Momenta Pharmaceuticals is a biotechnology company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Earnings Revisions. Equity, Margin Growth, and Sales Growth also get F’s. Share prices fell 23.2% over the past month. .
This is a rough week for Oncothyreon (NASDAQ:). The company’s rating falls to D from the previous week’s C. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Earnings Growth and Equity. Wall Street appears to agree with the stock downgrade, with share prices dropping 8.5% over the past month. .
Progenics Pharmaceuticals
(NASDAQ:) is having a tough week. The company’s rating falls from a C to a D rating. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock receives F’s in Earnings Momentum, Earnings Revisions, Equity, and Sales Growth. The stock price has fallen 29.3% over the past month. .
The rating of Ironwood Pharmaceuticals (NASDAQ:) declines this week from a C to a D. Ironwood Pharmaceuticals discovers, develops, manufactures, and commercializes marketed drugs. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 9.2% over the past month. .
The rating of Nymox Pharmaceutical (NASDAQ:) slips from a C to a D. Nymox Pharmaceutical is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. .
Trius Therapeutics‘ (NASDAQ:) rating weakens this week, dropping to a F versus last week’s D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. The stock price has fallen 16.5% over the past month. .
Louis Navellier’s proprietary stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool .
